Series B · Biotech & Pharma

Series B Biotech pitch decks that turn clinical data into conviction.

Series B biotech investors are underwriting clinical data and the strategy to reach a registrational or partnering inflection. The deck must present readouts with rigor, show how the data informs the next trial, and frame pipeline value for specialist and crossover funds.

At a glance

Typical deck length
15–20 slides plus data appendix
Who you're pitching
Growth-stage VCs, crossover funds and multi-stage firms writing $15–50M+ checks.
Lead with
Clinical results summary · Next-trial design · Regulatory interactions
Trusted by founders & teams at
PfizerSonyBayerMerckUPMCFarmers InsurancePella
What investors need to believe

What Series B Biotech investors need to believe.

A Biotech round at Series B turns on a handful of beliefs. Your deck should build each one before a partner has to ask.

The data is real and differentiated

Clinical results show safety and early efficacy that stand up to the standard of care.

The next trial is de-risked

Dose, population and endpoints for the next study are informed by data in hand.

The pipeline adds value

Additional programs or indications contribute meaningful upside to the story.

There's a path to a strategic outcome

Partnership, licensing or late-stage financing options are credible after the next readout.

Metrics & proof

What to lead with at Series B.

At this stage, these are the numbers and evidence that carry the room. Each one should tie out to your model and data room.

Clinical results summary

Present safety and efficacy data with appropriate statistics and caveats.

Next-trial design

Show how readouts informed dose, population and endpoint selection.

Regulatory interactions

Summarize agency feedback and designations obtained, if any.

Pipeline value drivers

Show each program's next milestone and its contribution to the opportunity.

Runway and financing plan

Show cash through the next major readout and the financing path beyond.

Recommended slide order

How to structure a Series B Biotech deck.

A 15–20 slides plus data appendix structure tuned for this round. Tap any slide for the full guide.

  1. Title Slide

    At Series B, the title slide often anchors on scale — the one-liner states the business you've become and the expansion this round funds.

  2. Traction Slide

    Lead with clinical data and regulatory progress, presented with honest caveats specialist investors will respect.

    Biotech-specific
  3. Business Model Slide

    At Series B, show economics improving with scale: expanding margins, rising revenue per customer and increasingly efficient acquisition.

  4. Go-to-Market Slide

    At Series B, focus on scaling and expansion — new segments, channels or regions — with evidence that efficiency holds as spend increases.

  5. Market Size Slide

    At Series B, the market slide should show expansion — adjacent segments, new products or geographies that grow the opportunity beyond the core.

  6. Product Slide

    At Series B, emphasize roadmap and platform breadth: how new modules or products extend the core and increase revenue per customer.

  7. Competition Slide

    Show a readout calendar alongside a differentiation table so timing and positioning are clear.

    Biotech-specific
  8. Team Slide

    At Series B, the team slide should show a scaling executive team with experience operating at the next stage of growth.

  9. Financials Slide

    Present cash runway against the clinical calendar, including contingency for trial delays.

    Biotech-specific
  10. The Ask & Use of Funds Slide

    At Series B, frame the raise around scaling and expansion — new markets, products or segments — with milestones that set up the next stage or a path to profitability.

Objections to pre-empt

What Biotech investors will push on at Series B.

Is the effect size meaningful versus standard of care?

How the deck answers it: Contextualize results against standard-of-care data and explain clinical meaningfulness, not just statistical significance.

Can the company fund a larger trial?

How the deck answers it: Show the financing strategy — this round, partnerships, non-dilutive sources — to reach the next inflection.

What does the competitive readout calendar look like?

How the deck answers it: Map competitor readouts on a timeline and show how you position around them.

What founders say

Trusted by founders. Backed by results.

They were able to give us insight into a comprehensive and emerging landscape. They provided further resources with case studies and data to make our arguments more compelling; while being timely and communicative. They're an asset to any team moving forward.
John McTernan
Sr. Director of Strategy | Pfizer
[They] were educated in the biopharma space and was able to give us insight into the landscape. They provided further resources/data to make our arguments more compelling. He was timely and communicative. An asset to any team moving forward.
Zander Ford
Founder | Conscious Founders
(For our acquisition of Modular Water), they really built the case with deep research. Highly professional. They took the time to work through a number of iterations of the project and maintained outstanding communication. Highly recommend.
Riggs Eckleberry
CEO | OriginClear HoldCo.
FAQ

Common questions. Clear answers.

How should a Series B biotech deck present clinical data?
Clearly and conservatively: the key safety and efficacy findings, the statistics behind them and their limitations, with full detail available in the data room. Overclaiming erodes specialist trust quickly.
Do crossover investors need a different biotech deck?
Often yes. Crossover funds weigh the path to public markets and pipeline value more heavily, so the narrative emphasizes the catalyst calendar and the long-term portfolio.
What does a custom engagement cost?
We're upfront about pricing: custom presentations start at $25K, and monthly packages are $15,000 — which include a team lead, researcher, analyst, and investor-relations expert for the price of one employee.
How fast can you turn it around?
Typical turnaround is 8–10 business days from the strategy session to final delivery. Expedited timelines are available when your raise is on a clock.
Free deck audit

Raising your Series B round? Get the deck right first.

Drop your details and we'll send a free deck audit — then jump on a 15-minute intro call to walk through exactly what to fix before you pitch.

  • We reply within 24 hours
  • Complete founder confidentiality
Prefer to talk first? Book a 1:1 intro call
Get your free deck audit